Answers are grounded in this paper and cite their sources.
Background The Idylla mutation test is a fully automated, real-time PCR-based assay for the targeted detection of cancer mutations in the key oncogenes KRAS , NRAS , BRAF and EGFR . The assay has a quick turnaround time and is cost effective lending itself for local implementation in a hospital setting. Methods The Idylla mutation test was validated on a total of 182 formalin-fixed paraffin-embedded (FFPE) cancer tissue samples, and a retrospective review of 115 patients who had the Idylla mutation test ordered at Tufts Medical Center (Boston, USA) was performed over 18 months. Results The validation yielded 100% sensitivity, 100% specificity, 100% overall accuracy, positive predictive value of 100%, and negative predictive value of 100%. The limit of detection (LOD) was ≤ 1%. The average turnaround time (TAT) from surgical specimen retrieval to result reporting was 14.7 days, from specimen receipt in the testing laboratory to reporting 2.8 days. The mutation detection rate was 27.4%. Conclusions The Idylla mutation test is highly accurate. To obtain the possible short turnaround time of the assay, efficient intradepartmental workflows are critical. The use of the assay in non-small cell lung cancer (NSCLC) is beneficial to resections in tumor stages 1–3. In cases where the Idylla groups multiple mutations into one reporting category, the actual underlying mutation cannot be identified. In instances where ambiguous results have clinical implications, as well as for normal Idylla results, follow-up with Next Generation Sequencing (NGS) is warranted.
No takes yet. Share an insight, caveat, or question.
Kappes et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: